Cargando…
Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T cell lymphomas
Autores principales: | Marie-Cardine, Anne, Viaud, Nicolas, Dujardin, Arnaud, Rachel, Joly, Granier, Nathalie, Gauthier, Laurent, Bonnafous, Cecile, Blery, Mathieu, Paturel, Carine, Bensussan, Armand, Bagot, Martine, Sicard, Helene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990323/ http://dx.doi.org/10.1186/2051-1426-1-S1-P45 |
Ejemplares similares
-
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas
por: Schmitt, Christian, et al.
Publicado: (2017) -
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma
por: Decroos, Amandine, et al.
Publicado: (2023) -
Targeting MICA with therapeutic antibodies for the treatment of cancer
por: Bonnafous, Cécile, et al.
Publicado: (2013) -
KIR2DL2, KIR2DL5A and KIR2DL5B Genes Induce Susceptibility to Dengue Virus Infection, while KIR3DL3 and KIR2DS5 Confer Protection
por: Tapsoba, Aziz Sidi Aristide, et al.
Publicado: (2022) -
Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Sézary Patient-Derived Xenograft Mouse Model
por: Habault, Justine, et al.
Publicado: (2022)